Pinealon + Semax + NAD+ Research Data

Natural Aminos Research Stack or Formula of the Day

Pinealon + Semax + NAD+

Neuroprotection, Neuroplasticity & Cellular-Energy Research Spotlight

Compound Identity & Evidence Context

Pinealon, Semax and NAD+ occupy three different layers of neurobiology. Pinealon is the short tripeptide Glu-Asp-Arg (EDR), developed in Russian peptide-bioregulation research and studied for neuronal stress resistance, dendritic structure, oxidative DNA damage, gene-expression regulation and age-related cognitive decline. Semax is the synthetic heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, derived from an ACTH(4-7) sequence with an added Pro-Gly-Pro segment, and is studied mainly for neuroprotection, neuroplasticity, BDNF-related signaling, stroke rehabilitation and cognitive effects. NAD+ is not a peptide; it is an essential cellular redox coenzyme and signaling substrate involved in ATP-generating metabolism, sirtuin activity, PARP-dependent DNA repair and numerous stress-response pathways.

The evidence maturity differs sharply. Pinealon has a broad preclinical literature and several Russian human observational/clinical reports, but the human evidence is small, geographically concentrated and not comparable to modern multinational randomized development programs. Semax has more direct human neurorehabilitation and neuroimaging evidence, but most clinical research is also Russian, and FDA's July 2026 review concluded that evidence was insufficient to support Semax for cerebral ischemia and that important safety and pharmacokinetic gaps remain. NAD+-targeted research is global and much larger, although human clinical benefit is considerably less consistent than the underlying biochemistry.

No peer-reviewed human, animal or cell study was identified that administered Pinealon + Semax + NAD+ together as one defined intervention. No direct Pinealon + Semax, Pinealon + NAD+, or Semax + NAD+ combination trial was identified. The complete stack must therefore be evaluated as a mechanistic hypothesis, not a proven combination.

Benefits

Pinealon

Pinealon's most consistent experimental signal is protection of neurons and other cells from stress. In a 2011 study, Pinealon reduced reactive-oxygen-species accumulation and necrotic cell death in cerebellar granule cells, neutrophils and PC12 cells while altering ERK1/2 signaling and cell-cycle behavior. These findings support an antioxidant and cytoprotective effect, but they were obtained in cell systems rather than clinical participants.

The peptide has also been studied in aging and neurodegeneration models. A 2020 review of EDR/Pinealon summarized evidence for reduced neuronal apoptosis, preservation of dendritic spines in Alzheimer- and Huntington-related models, modulation of antioxidant enzymes, serotonin-related signaling and gene-expression pathways. These mechanisms remain largely preclinical and are strongly associated with a single Russian research network.

A useful modern update came in 2024 from a human-derived neuronal-aging model. Researchers transdifferentiated fibroblasts from elderly donors into induced cortical neurons and reported that EDR/Pinealon increased dendritic arborization and reduced oxidative DNA damage. Importantly, EDR did not improve every aging marker: mitochondrial and lysosomal activity and p16 were not meaningfully changed. This narrows the claim from broad cellular rejuvenation to selected structural and DNA-stress effects.

A 2025 study further complicated the geroprotective narrative. In induced neuronal differentiation experiments, EDR did not produce the strongest senescence effects; AEDG and KED, rather than EDR, reduced p21 or beta-galactosidase more clearly. Pinealon therefore should not be described as uniformly reversing neuronal senescence.

Human evidence is weak. A 2015 Russian study involving 32 adults aged 41-83 with chronic polymorbidity and organic brain syndrome reported improvements in central-nervous-system and biological-age indicators after Pinealon and Vesugen, but the design combined peptides and does not isolate Pinealon cleanly. Other Russian occupational and gerontology reports similarly use mixed interventions and nonstandard endpoints. These findings are hypothesis-generating rather than definitive clinical proof.

Semax

Semax has substantially more human evidence than Pinealon. Russian clinical studies have examined intranasal Semax in ischemic stroke, cerebrovascular disease and neurorehabilitation. A 110-patient rehabilitation study reported that Semax increased plasma BDNF and was associated with faster improvement in Barthel-index scores and motor recovery, particularly when rehabilitation began earlier. The study supports a neurotrophin-linked clinical signal but does not meet the evidentiary standard of a large modern multinational randomized pivotal trial.

Semax also has human neuroimaging data. A resting-state fMRI study in healthy volunteers found changes in default-mode-network connectivity after intranasal Semax. A separate placebo-controlled fMRI study comparing Semax, Selank and placebo in separate groups found distinct connectivity effects, providing direct human evidence that Semax can alter functional brain-network organization.

Mechanistically, Semax is often linked to BDNF/TrkB signaling, neurotrophin expression, MAPK/ERK pathways, glutamatergic signaling, oxidative-stress responses and inflammatory regulation. Much of this mechanistic work is preclinical. The human BDNF rehabilitation study provides some translational support but does not prove that every molecular pathway described in animal studies operates identically in humans.

FDA's July 2026 Pharmacy Compounding Advisory Committee review is an important counterweight to the older positive literature. FDA concluded that there was insufficient evidence of effectiveness for cerebral ischemia, found insufficient clinical information to characterize the intranasal safety profile, found no safety data for the proposed subcutaneous route, identified no published human pharmacokinetic studies, and noted a potential bleeding concern based on published antithrombotic findings. FDA also did not identify published clinical immunogenicity studies.

NAD+

NAD+ is fundamental to cellular energy and redox metabolism. The NAD+/NADH couple is central to glycolysis, the tricarboxylic-acid cycle and oxidative phosphorylation, while NAD+ also serves as a substrate for sirtuins, PARPs, CD38 and other enzymes involved in stress responses, DNA repair, calcium signaling and metabolic regulation. This makes NAD+ biologically relevant to neurons, which are highly dependent on mitochondrial ATP production and efficient DNA-damage responses.

Human evidence for directly administered NAD+ has historically been much weaker than evidence for the precursors NR and NMN. A 2019 six-hour intravenous NAD+ pilot demonstrated rapid removal and metabolism of infused NAD+ but was pharmacokinetic rather than an efficacy trial. A 2026 systematic review found 33 human NAD-related intervention studies but no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.

A major 2026 update came from a double-blind randomized Phase 0/1b trial of an oral physically modified NAD+ formulation in healthy adults aged 45-75. Five days of treatment increased intracellular whole-blood NAD by 53% versus placebo without raising plasma NAD. The formulation was well tolerated, but no secondary clinical, vital-sign, wellbeing or wearable endpoint survived multiplicity correction. This is strong direct NAD+ target-engagement evidence, not proof of meaningful functional benefit.

The broader precursor literature remains mixed. A 2025 Nature Metabolism review concluded that evidence for a consistent age-related NAD+ decline in humans remains limited and tissue specific, while human NR/NMN trials generally show reliable biochemical target engagement but limited, heterogeneous or endpoint-specific clinical efficacy.

What the Formulas Are Studied For

Pinealon Research Areas

• Neuronal oxidative-stress resistance and cell survival.

• Dendritic spine preservation and dendritic arborization.

• Age-related neuronal changes and oxidative DNA damage.

• Alzheimer- and Huntington-related preclinical models.

• Gene-expression and chromatin/DNA-interaction hypotheses.

• Serotonin, ERK/MAPK and antioxidant-enzyme regulation.

• Hypoxia and ischemia-related animal models.

• Low-certainty gerontology and occupational-health studies in Russia.

Semax Research Areas

• Ischemic stroke and post-stroke neurorehabilitation.

• BDNF and neurotrophin signaling.

• Cerebral ischemia and hypoxia tolerance.

• Cognitive and attention-related research.

• Resting-state brain-network connectivity.

• Inflammatory and oxidative-stress regulation in nervous tissue.

• Glutamatergic and MAPK/ERK signaling.

• Migraine and trigeminal neuralgia were among uses reviewed by FDA in 2026, without adequate evidence to establish effectiveness.

NAD+ Research Areas

• Cellular redox balance and mitochondrial ATP production.

• Sirtuin-dependent metabolic and stress-response signaling.

• PARP-dependent DNA repair.

• CD38-linked NAD consumption and aging biology.

• NR and NMN precursor supplementation in human metabolic and aging studies.

• Direct NAD+ pharmacokinetics and newer direct oral NAD+ target-engagement trials.

• Neurodegenerative-disease and brain-energy research.

• Healthy-aging research, for which clinical efficacy remains unproven.

Published Research - Worldwide Evidence Review

Pinealon - Russia and Modern Human-Derived Cell Models

Pinealon research remains geographically concentrated in Russia. Foundational work from St. Petersburg and related institutes reported reduced ROS and necrotic death, altered ERK1/2 signaling, behavioral changes in animal stress models and hypothesized interactions with gene-regulatory systems.

Russian biochemical work also showed that fluorescently labeled Pinealon can enter cultured human HeLa-cell nuclei and interact in vitro with selected DNA oligonucleotide sequences. These findings support a possible gene-regulatory mechanism but are not equivalent to demonstrating gene-specific therapeutic effects in the human brain.

The 2015 human gerontology study enrolled 32 adults aged 41-83 and used Pinealon together with Vesugen. Investigators reported improvement in CNS and biological-age measures but also observed prooxidant chemiluminescence changes and reduced circulating CD34+ cells. Because two peptides were administered and the design was not a modern randomized monotherapy trial, the Pinealon-specific effect remains uncertain.

The 2024 human-derived neuronal-aging model provides better mechanistic resolution. EDR/Pinealon increased dendritic complexity and reduced oxidative DNA damage in induced neurons derived from elderly donors, but did not improve mitochondrial or lysosomal activity. The 2025 senescence study again showed that EDR was not the strongest peptide for p21 or beta-galactosidase outcomes.

Semax - Russia, Human Neuroimaging and 2026 U.S. Regulatory Reassessment

Semax was developed in Russia and has been used there in neurological practice. Earlier Russian publications describe memory, attention, hypoxia-resistance and cerebrovascular effects, but many studies predate modern CONSORT-style reporting and are difficult to compare with contemporary international drug-development standards.

The 110-patient ischemic-stroke rehabilitation study is one of the more clinically relevant reports. Semax treatment was associated with increased plasma BDNF and improved rehabilitation measures. These results support a neuroplasticity hypothesis, though the study does not provide the same certainty as a large placebo-controlled multicenter Phase III trial.

Human fMRI studies have demonstrated measurable brain-network effects after intranasal Semax, including changes in default-mode-network connectivity. Such imaging findings prove central nervous system activity but do not by themselves establish durable cognitive or functional clinical benefit.

FDA's July 2026 review assessed Semax for cerebral ischemia, migraine and trigeminal neuralgia. FDA concluded that effectiveness evidence was insufficient for cerebral ischemia and emphasized missing intranasal safety characterization, no subcutaneous safety data, no published human pharmacokinetic studies and no clinical immunogenicity studies. This current regulatory assessment should temper claims based solely on older Russian experience.

NAD+ - United States, Netherlands, Japan and Global Clinical Research

NAD+-targeted clinical research is far more geographically diverse. U.S., European and Japanese groups have evaluated direct NAD+, NR and NMN. Human studies consistently show that NAD-related interventions can alter NAD metabolites, but functional outcomes vary greatly by tissue, baseline state and endpoint.

A 2025 Nature Metabolism review from Amsterdam UMC and international collaborators concluded that the human evidence for age-related NAD decline is less consistent than commonly portrayed and that precursor efficacy is limited and tissue specific. A 2025 Nature Aging review similarly emphasized unresolved questions involving dose, route, frequency, long-term safety and interindividual response.

The 2026 PRISMA-guided systematic review identified 113 intervention studies, including 33 human trials. Human NR/NMN studies generally showed biochemical target engagement and acceptable short-term tolerability, while clinical healthspan outcomes were heterogeneous and often null. The review found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness.

The 2026 RENEWAL-NAD+ randomized study is the strongest new direct-NAD target-engagement evidence. In 60 randomized healthy adults, with 50 in the primary analysis, five days of oral LNAD+ increased intracellular whole-blood NAD by 53% versus placebo. No secondary clinical or wearable-derived endpoint survived multiplicity correction, keeping the interpretation firmly at the biomarker level.

Direct Research on Pinealon + Semax + NAD+ Together

No peer-reviewed study was identified that administered Pinealon, Semax and NAD+ together. No controlled pairwise combination study was identified for Pinealon + Semax, Pinealon + NAD+, or Semax + NAD+.

Pinealon and Semax are discussed together in Russian reviews of peptide neuroprotectors, but class-level discussion is not combination evidence. Likewise, NAD+-related reviews discuss mitochondrial energy, DNA repair and neurodegenerative disease without testing either peptide as a co-intervention.

Therefore, the three-way stack cannot be described as clinically synergistic. Its plausibility comes from linking distinct but partially overlapping mechanisms: neuronal stress resistance, neurotrophin-linked plasticity and cellular energy/redox support.

Theory of the Stack - How the Combination Could Work

1. Neuronal Stress Resistance - Pinealon Layer

Pinealon would provide the cellular-protection layer. The strongest mechanistic rationale is reduction of oxidative DNA damage, preservation of dendritic architecture and modulation of stress-responsive signaling. In theory, this could make aging or injured neurons more resilient to metabolic and inflammatory stress.

2. Neuroplasticity and Rehabilitation Signaling - Semax Layer

Semax would provide the neurotrophic/plasticity layer. Human rehabilitation data linking Semax with higher plasma BDNF, together with fMRI evidence of altered connectivity, support the idea that Semax may influence the brain's adaptive response to injury or cognitive demand.

3. Cellular Energy and DNA-Repair Capacity - NAD+ Layer

NAD+ would provide the metabolic layer. Neurons have high ATP requirements and depend on intact redox balance, mitochondrial metabolism and DNA-repair systems. Raising intracellular NAD could theoretically support ATP production, sirtuin activity and PARP-mediated repair during periods of neuronal stress.

4. Why the Three Mechanisms Could Be Complementary

The strongest systems-level theory is that Pinealon protects neuronal structure, Semax promotes adaptive signaling and plasticity, and NAD+ supports the metabolic energy needed to sustain those processes. These roles are more complementary than combining three agents that target the same receptor.

5. Oxidative-Stress Biology Creates Partial Redundancy

Pinealon is repeatedly described as reducing oxidative stress, Semax has preclinical antioxidant and inflammatory effects, and NAD+ metabolism is tightly linked to redox balance. This creates overlap. If oxidative injury is the main bottleneck, all three components may converge on the same problem rather than provide fully independent benefits.

6. Plasticity Requires Energy, but Energy Does Not Guarantee Plasticity

The NAD+ component is mechanistically attractive because synaptic remodeling, dendritic growth, axonal transport and protein synthesis all require energy. However, raising NAD is not equivalent to producing neuroplasticity. The 2026 direct NAD+ trial increased intracellular NAD strongly without demonstrating corrected functional benefits over five days.

7. Pinealon's Human Evidence Is the Weakest Link

Pinealon contributes an appealing dendritic and oxidative-DNA-damage theory, but its human evidence is far weaker than the Semax and NAD+ evidence bases. Many human reports combine Pinealon with other peptides, use small samples or employ unconventional gerontological endpoints. The full stack should therefore not inherit a level of certainty greater than its weakest component.

8. Semax Safety and Route Uncertainty Matter

Any theory of Semax-enhanced neuroplasticity must be balanced against the 2026 FDA review. Intranasal safety is not fully characterized, no subcutaneous safety data were identified, human pharmacokinetics are unpublished and possible antithrombotic effects raise concern in selected populations. Combination use does not remove these uncertainties.

9. NAD+ Route Matters

Most clinical evidence concerns NR/NMN or the new oral LNAD+ formulation, not generic parenteral NAD+. An intravenous NAD+ pilot demonstrated metabolism but not clinical efficacy, and the 2026 systematic review found no eligible IV/IM outcomes trials for anti-aging or wellness. Claims about an injectable stack should not be borrowed from oral precursor studies.

10. Neuroprotection Is Not the Same as Cognitive Enhancement

All three components are often described in cognitive or healthy-aging contexts, but protecting neurons from injury and improving measurable cognition are different endpoints. Pinealon's dendritic findings, Semax's BDNF/fMRI effects and NAD+'s biochemical target engagement do not collectively prove improved memory, executive function or long-term cognitive performance in healthy people.

Possible Overall Benefit - Theoretical, Not Proven

The most defensible theoretical benefit of Pinealon + Semax + NAD+ is integrated support for stressed or aging neural tissue. Pinealon could theoretically preserve neuronal structure and reduce oxidative DNA injury, Semax could increase neurotrophic/plasticity signaling and adaptive network activity, and NAD+ could improve the intracellular metabolic environment needed for energy-intensive repair and synaptic remodeling.

In post-injury or neurorehabilitation research, this could theoretically combine cellular resilience, neuroplasticity and metabolic support. In healthy-aging research, the concept would be maintenance of neuronal structure and bioenergetic capacity rather than proven reversal of cognitive aging.

The complete stack remains unproven. No direct combination trial exists, Pinealon's clinical evidence is weak, FDA considers Semax effectiveness and safety evidence insufficient for nominated uses, and NAD+ target engagement has not consistently translated into functional human outcomes.

Why More Research Is Needed

• No published study has tested Pinealon + Semax + NAD+ together, and no direct pairwise combination study was identified.

• Pinealon human evidence is small, geographically concentrated and frequently involves co-administration with other peptide preparations.

• Pinealon's newer human-derived neuronal data show selected benefits but no consistent improvement across mitochondrial, lysosomal or senescence markers.

• Semax clinical research is concentrated in Russia and often predates modern multinational pivotal-trial standards.

• FDA's 2026 review concluded that Semax effectiveness evidence was insufficient for cerebral ischemia.

• FDA found inadequate intranasal safety characterization, no proposed subcutaneous-route safety data, no published human pharmacokinetic studies and no clinical immunogenicity studies for Semax.

• Potential Semax antithrombotic activity raises a theoretical bleeding concern in susceptible populations or in combination with other agents affecting hemostasis.

• Direct NAD+ human efficacy evidence remains much smaller than the NR/NMN precursor literature.

• The 2026 direct oral NAD+ randomized trial demonstrated strong target engagement but no secondary functional endpoint that survived multiplicity correction.

• A 2026 systematic review found no eligible intravenous or intramuscular NAD+ outcomes trials for anti-aging or wellness indications.

• The three components overlap on oxidative-stress biology, so controlled studies are needed to distinguish real complementarity from redundancy.

• Future research should include objective cognitive testing, neuroimaging, BDNF and inflammatory markers, NAD metabolomics, mitochondrial measures and long-term safety rather than relying only on subjective wellbeing.

• Population-specific trials are needed because post-stroke rehabilitation, neurodegenerative disease, healthy aging and cognitive enhancement are biologically different indications.

Research Summary

Pinealon + Semax + NAD+ is a biologically coherent neuroprotection-neuroplasticity-bioenergetics stack with sharply uneven evidence. Pinealon contributes preclinical and human-derived-cell evidence for dendritic support and oxidative-DNA-damage reduction, but its human clinical literature is weak. Semax contributes more direct human neurorehabilitation and neuroimaging evidence, including BDNF-associated recovery findings, but FDA's 2026 review still found insufficient effectiveness and important safety-data gaps. NAD+ contributes the strongest and broadest modern mechanistic evidence, including a 2026 randomized trial showing a 53% increase in intracellular whole-blood NAD after five days, without corrected functional benefit.

The stack theory is strongest as a division of labor: Pinealon for neuronal stress resistance and structural preservation, Semax for neurotrophic/plasticity signaling, and NAD+ for cellular energy and repair capacity. The theory is weakened by overlap in oxidative-stress biology and by the absence of any direct combination study. The complete stack remains an experimental hypothesis rather than a validated cognitive, neurorehabilitation or healthy-aging intervention.

Selected Sources

• Khavinson VK, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011. PMID: 21978084. DOI: 10.1089/rej.2011.1172.

• Khavinson V, et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159. PMID: 33396470. PMCID: PMC7795577. DOI: 10.3390/molecules26010159.

• Kraskovskaya N, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 2024. PMID: 39518916. PMCID: PMC11546785.

• Sakhenberg E, et al. The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation. Current Issues in Molecular Biology. 2025;47(9):739. PMID: 41020860. PMCID: PMC12468822. DOI: 10.3390/cimb47090739.

• Meshchaninov VN, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology. 2015;28(1):62-67. PMID: 26390612.

• Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro interaction with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID: 22117547.

• Umnov RS, Linkova NS, Khavinson VK. Neuroprotective effects of peptide bioregulators in people of various age. Advances in Gerontology. 2013;26(4):671-678. PMID: 24738258.

• The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. 110-patient rehabilitation study reporting BDNF and functional outcomes. PMID: 29798983.

• Lebedeva IS, et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018;165(5):653-656. PMID: 30225715. DOI: 10.1007/s10517-018-4234-3.

• U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee materials: Semax-related bulk drug substances. FDA concluded effectiveness evidence was insufficient for cerebral ischemia and identified major safety and pharmacokinetic gaps.

• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current Semax entry notes potential immunogenicity risk from aggregation and peptide-related impurities.

• Kornilov SA, et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. Geroscience. 2026. PMID: 42530810. DOI: 10.1007/s11357-026-02399-1.

• Grant R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019. PMID: 31572171. PMCID: PMC6751327. DOI: 10.3389/fnagi.2019.00257.

• Vinten KT, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. 2025;7(10):1974-1990. PMID: 41083806. DOI: 10.1038/s42255-025-01387-7.

• Zhang J, et al. Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging. 2025. PMID: 40926126.

• Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. PMID: 41655607. DOI: 10.1016/j.arr.2026.103057.

Theory vs. Proof - Verdict

What is supported by evidence: Pinealon has reproducible preclinical neuroprotective and oxidative-stress effects plus newer human-derived-neuron evidence for dendritic arborization and reduced oxidative DNA damage; Semax has human neurorehabilitation and neuroimaging data, including BDNF-associated findings; and NAD+ can be raised in humans through precursor strategies and, in a 2026 randomized direct-NAD formulation trial, through short-term oral NAD+ exposure.

What is not proven: that Pinealon produces clinically meaningful cognitive or neurodegenerative benefits in a modern randomized human trial; that Semax is effective for cerebral ischemia under contemporary regulatory standards; that NAD+ augmentation produces broad cognitive or healthy-aging benefits; or that combining Pinealon, Semax and NAD+ is additive, synergistic or safer than any individual component.

Verdict - theory vs. proof: the mechanistic theory is moderately strong and more complementary than many same-pathway peptide stacks. Pinealon plausibly contributes neuronal stress resistance and dendritic support, Semax contributes the strongest neurotrophic/plasticity signal, and NAD+ contributes cellular redox, energy and DNA-repair capacity. The main weaknesses are evidence asymmetry, geographic concentration of the peptide literature, overlap on oxidative-stress pathways and the complete absence of direct combination data. Overall, Pinealon + Semax + NAD+ is best classified as a plausible neuroprotection-plus-neuroplasticity-plus-bioenergetics hypothesis with meaningful component-level mechanistic evidence, modest human evidence for Semax, limited human evidence for Pinealon, strong NAD+ target-engagement evidence and no direct proof of superior cognitive or neurological outcomes from the complete stack.

Research & Educational Use Only !!